Evidence map›Paper›PMID 31734439›Full record

ArticleNeurobiology of aging2020

Apoptosis signal regulating kinase 1 deletion mitigates α-synuclein pre-formed fibril propagation in mice.

Jie Zhang, Eun S Park, Hye-Jin Park, Run Yan, Magda Grudniewska, Xiaopei Zhang, Stephanie Oh, Xue Yang, Jean Baum, M Maral Mouradian

Abstract read
In one paragraph

Article in Neurobiology of aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Clinical potential and current progress of mesenchymal stem cells for Parkinson's disease: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Pooled it
  3. Review
  4. Targeting ASK1 signaling in neurodegeneration: molecular insights and therapeutic promise.Apoptosis : an international journal on programmed cell death · 2025
    Review
  5. Review
  6. Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
  7. Article
  8. Article
  9. MicroRNA-7 Protects Against Neurodegeneration Induced by α-Synuclein Preformed Fibrils in the Mouse Brain.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jie ZhangRobert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, NJ, USA.
Eun S ParkRobert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, NJ, USA.
Hye-Jin ParkRobert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, NJ, USA.
Run YanRobert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, NJ, USA.
Magda GrudniewskaRobert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, NJ, USA.
Xiaopei ZhangRobert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, NJ, USA.
Stephanie OhRobert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, NJ, USA.
Xue YangDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, USA.
Jean BaumDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, USA.
M Maral MouradianRobert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, NJ, USA. Electronic address: m.mouradian@rutgers.edu.

Funding

Manipulating Gene Expression in the Dyskinesias of Parkinson's DiseaseR01NS073994 · NINDS · EMORY UNIVERSITY · PI MOURADIAN, M. MARAL, PAPA, STELLA M · 2011 to 2016
$2.4M
PP2A Dysregulation in the Pathogenesis of alpha-SynucleinopathiesR01NS101134 · NINDS · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI MOURADIAN, M. MARAL, NICHOLLS, RUSSELL E · 2017 to 2021
$2.3M
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's DiseasR01AT006868 · NCCIH · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI MOURADIAN, M. MARAL, STOCK, JEFFRY B · 2012 to 2016
$2.2M
Neuroprotective Activity of DJ-1 in Parkinson's DiseaseR01NS059869 · NINDS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI MOURADIAN, M. MARAL · 2007 to 2011
$1.7M
NMR Based Studies of Alpha-Synuclein Aggregation and InhibitionR01GM110577 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI BAUM, JEAN S · 2015 to 2018
$1.3M
Developing Novel RNA-Based Therapeutics for Parkinson's DiseaseR33NS096032 · NINDS · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI DISNEY, MATTHEW D, MOURADIAN, M. MARAL · 2018 to 2019
$843k
Developing Novel RNA-Based Therapeutics for Parkinson's DiseaseR21NS096032 · NINDS · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI DISNEY, MATTHEW D, MOURADIAN, M. MARAL · 2017 to 2017
$452k
Anti-apoptotic Function of DJ-1 in Parkinson's DiseaseR21NS053517 · NINDS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI MOURADIAN, M. MARAL · 2006 to 2007
$399k
NCCIH NIH HHS R01 AT006868NIGMS NIH HHS R01 GM110577NINDS NIH HHS R01 NS059869NINDS NIH HHS R01 NS073994NINDS NIH HHS R01 NS101134NINDS NIH HHS R21 NS053517NINDS NIH HHS R21 NS096032NINDS NIH HHS R33 NS096032
6 · The paper itself

Abstract

α-Synuclein (α-Syn) is a key pathogenic protein in α-synucleinopathies including Parkinson disease and dementia with Lewy bodies. Accumulating evidence has shown that misfolded fibrillar α-Syn is transmitted from cell-to-cell, a phenomenon that correlates with clinical progression of the disease. We previously showed that deleting the MAP3 kinase apoptosis signal-regulating kinase 1 (ASK1), which is a central player linking oxidative stress with neuroinflammation, mitigates the phenotype of α-Syn transgenic mice. However, whether ASK1 impacts pathology and disease progression induced by recombinant α-Syn pre-formed fibrils (PFF) remains unknown. Here, we compared the neuropathological and behavioral phenotype of ASK1 knock-out mice with that of wild-type mice following intrastriatal injections of α-Syn PFF. At 6 months post-injections, ASK1 null mice exhibited reduced amount of phosphorylated α-Syn aggregates in the striatum and cortex, and less pronounced degeneration of the nigrostriatal pathway. Additionally, the neuroinflammatory reaction to α-Syn PFF injection and propagation seen in wild-type mice was attenuated in ASK1 knock-out animals. These neuropathological markers were associated with better behavioral performance. These data suggest that ASK1 plays an important role in pathological α-Syn fibril transmission and, consequently, may impact disease progression. These findings collectively support inhibiting ASK1 as a disease modifying therapeutic strategy for Parkinson disease and related α-synucleinopathies.

Indexed as

alpha-SynucleinAnimalsApoptosisInflammationMAP Kinase Kinase Kinase 5Mice, Inbred C57BLMice, KnockoutParkinson DiseaseProtein Aggregation, PathologicalSignal Transductionalpha-SynucleinMap3k5 protein, mouseMAP Kinase Kinase Kinase 5Alpha-synucleinASK1NeuroinflammationParkinson diseasePre-formed fibrilsPropagation

Identifiers

PMID31734439
PMCPMC7064162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.